ATE546147T1 - Zusammensetzungen und verfahren zur behandlung und vorbeugung von kardiomyopathie und herzerkrankung - Google Patents

Zusammensetzungen und verfahren zur behandlung und vorbeugung von kardiomyopathie und herzerkrankung

Info

Publication number
ATE546147T1
ATE546147T1 AT06736222T AT06736222T ATE546147T1 AT E546147 T1 ATE546147 T1 AT E546147T1 AT 06736222 T AT06736222 T AT 06736222T AT 06736222 T AT06736222 T AT 06736222T AT E546147 T1 ATE546147 T1 AT E546147T1
Authority
AT
Austria
Prior art keywords
treating
methods
heart disease
compositions
preventing cardiomyopathy
Prior art date
Application number
AT06736222T
Other languages
German (de)
English (en)
Inventor
Joseph Metzger
Dewayne Townsend
Soichiro Yasuda
Dan Michele
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE546147T1 publication Critical patent/ATE546147T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06736222T 2005-02-25 2006-02-27 Zusammensetzungen und verfahren zur behandlung und vorbeugung von kardiomyopathie und herzerkrankung ATE546147T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65657005P 2005-02-25 2005-02-25
PCT/US2006/006862 WO2006091941A2 (en) 2005-02-25 2006-02-27 Compositions and methods for treating and preventing cardiomyopathy and heart disease

Publications (1)

Publication Number Publication Date
ATE546147T1 true ATE546147T1 (de) 2012-03-15

Family

ID=36928113

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06736222T ATE546147T1 (de) 2005-02-25 2006-02-27 Zusammensetzungen und verfahren zur behandlung und vorbeugung von kardiomyopathie und herzerkrankung

Country Status (8)

Country Link
US (2) US7846426B2 (https=)
EP (1) EP1853280B1 (https=)
JP (1) JP5042041B2 (https=)
AT (1) ATE546147T1 (https=)
AU (2) AU2006216420B2 (https=)
CA (1) CA2599219C (https=)
ES (1) ES2380047T3 (https=)
WO (1) WO2006091941A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2046348B1 (en) * 2006-08-01 2015-07-22 Phrixus Pharmaceuticals, Incorporated Use of poloxamer for the prevention and/or treatment of heart failure
WO2008124088A2 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
WO2009070793A1 (en) * 2007-11-29 2009-06-04 Pluromed, Inc. Endoscopic mucosal resectioning using purified inverse thermosensitive polymers
US8852568B2 (en) 2007-12-17 2014-10-07 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
US9867547B2 (en) 2012-11-29 2018-01-16 Siemens Healthcare Gmbh System and method to calculate cardiac characteristics
WO2015050581A1 (en) * 2013-04-19 2015-04-09 Cedars-Sinai Medical Center Phosphodiesterase 5a inhibitors for the treatment of muscular dystrophy
EP3057598A1 (en) * 2013-10-16 2016-08-24 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
JP6747748B2 (ja) 2014-07-07 2020-08-26 ライフラフト バイオサイエンシーズ，インコーポレイテッド 長期循環物質のないポロクサマー組成物、その産生方法およびその使用
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
US20220023333A1 (en) * 2019-05-06 2022-01-27 Elena Valentinovna ARSHINTSEVA Method for increasing cancer patient's haemoglobin level

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2140408T3 (es) 1991-03-19 2000-03-01 Cytrx Corp Copolimeros de polioxipropileno/polioxietileno con actividad biologica mejorada.
JPH05178760A (ja) 1991-06-03 1993-07-20 Alpha Therapeutic Corp 心筋梗塞治療剤
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US6761824B2 (en) 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
WO2002065834A2 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol

Also Published As

Publication number Publication date
JP5042041B2 (ja) 2012-10-03
CA2599219A1 (en) 2006-08-31
AU2010214636A1 (en) 2010-09-16
US20110044935A1 (en) 2011-02-24
CA2599219C (en) 2011-09-20
JP2008531598A (ja) 2008-08-14
WO2006091941A2 (en) 2006-08-31
EP1853280B1 (en) 2012-02-22
US7846426B2 (en) 2010-12-07
EP1853280A4 (en) 2008-10-29
US20080260681A1 (en) 2008-10-23
US8580245B2 (en) 2013-11-12
AU2006216420A1 (en) 2006-08-31
EP1853280A2 (en) 2007-11-14
WO2006091941A3 (en) 2007-01-04
ES2380047T3 (es) 2012-05-08
AU2006216420B2 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
CY1119269T1 (el) Θεραπεια βλαβων που προκαλουνται απο ιους
EA200501592A1 (ru) Способы и композиции для введения агонистов trpv1
EA200970446A1 (ru) Связывающиеся с альбумином молекулы и их применение
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
EA201071178A1 (ru) Усовершенствованные способы гашения нежелательных побочных реакций при патогенной инактивации эритроцитов
CR20120649A (es) Compuestos, composiciones de tioacetato y métodos de uso
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
CY1112999T1 (el) Αναστολεις ιου ηπατιτιδας c
EA200870164A1 (ru) Лечение вирусного гепатита
MX2012009088A (es) Anticuerpos que se enlazan a lisil oxidasa-tipo2 (loxl2) y metodos de uso para los mismos.
ECSP10010310A (es) Nuevos compuestos y composiciones y métodos de uso
EA201890516A1 (ru) Клинические композиции
ATE546147T1 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von kardiomyopathie und herzerkrankung
PH12013500467A1 (en) Pharmaceutical composition
MX2012015063A (es) Metodos y composiciones para mejorar la movilizacion de celulas madre.
EA201170571A1 (ru) Способы и композиции для улучшения когнитивной функции
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
RU2014146291A (ru) Способ использования сложных эфиров азелаиновой кислоты для модуляции передачи сигналов, медиируемых биологическими молекулами
EA201000277A1 (ru) Соединения для лечения гепатита с
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
EA201190344A1 (ru) Составы для лечения боли в глубоких тканях